Back
Halozyme Therapeutics Stock Predictions
Unlock the Ultimate Gold Play: $20 for a 1 Oz Stake in Gold!
Don't miss out-click here for urgent details on the #1 gold play of the year!
Sell
30
HALO
Halozyme Therapeutics
Last Price:
51.64
Seasonality Move:
20.13%
7 Day Trial
ALL ACCESS PASS
$
7
Forget Bitcoin - This Is the Real Opportunity of 2024
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.Halozyme Therapeutics Stock Forecast
- Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 25.4% based on the past 20 years of stock performance.
- Halozyme Therapeutics has risen higher in 13 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 65%
-
Is Halozyme Therapeutics Stock Undervalued?
The current Halozyme Therapeutics [HALO] share price is $50.65. The Score for HALO is 30, which is 40% below its historic median score of 50, and infers higher risk than normal. - HALO is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
Will Halozyme Therapeutics Stock Go Up Next Year?
- Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 25.4% based on the past 20 years of stock performance.
Halozyme Therapeutics Stock Rating
Sell
30
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics overpriced?
- Halozyme Therapeutics has risen higher in 13 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 65%
Halozyme Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
halozyme.com
52-Week Data
52-Week High:
65.53
52-Week Low:
32.83
Prediction Charts
Market Cap:
6.42B
Price in USD:
50.65
Volume:
3.18M
Beta:
1.47
Technical Analysis
SMA50:
58.64
SMA100:
54.54
SMA200:
46.49
52-Wk Change:
36.74%
Stock Predictions
-
Is Halozyme Therapeutics stock public?
Yes, Halozyme Therapeutics is a publicly traded company. -
What is the Halozyme Therapeutics stock quote today?
The Halozyme Therapeutics stock price is 50.65 USD today. -
How to buy Halozyme Therapeutics stock online?
You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Sep-20 | 59.83 | 59.26 | 59.83 | 58.71 |
| Sep-23 | 59.62 | 58.53 | 59.62 | 58.41 |
| Sep-24 | 58.60 | 56.21 | 58.60 | 55.95 |
| Sep-25 | 56.50 | 55.87 | 56.67 | 55.43 |
| Sep-26 | 55.91 | 56.95 | 57.04 | 55.80 |
| Sep-27 | 57.35 | 56.97 | 58.04 | 56.84 |
| Sep-30 | 56.87 | 57.23 | 57.59 | 56.53 |
| Oct-1 | 56.97 | 56.62 | 57.19 | 55.89 |
| Oct-2 | 56.55 | 58.16 | 58.39 | 56.20 |
| Oct-3 | 58.12 | 60.43 | 62.00 | 57.63 |
| Oct-4 | 60.56 | 59.18 | 61.56 | 58.51 |
| Oct-7 | 57.92 | 53.85 | 57.98 | 53.32 |
| Oct-8 | 54.33 | 54.13 | 55.00 | 53.25 |
| Oct-9 | 54.00 | 50.65 | 54.41 | 49.63 |
Halozyme Therapeutics Earnings
Halozyme Therapeutics Earnings Report: Per Share Halozyme Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.
Halozyme Therapeutics Forecast Revenue Growth
Halozyme Therapeutics Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics and historical quarterly revenue growth:
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.18 per share, and an increase next year of $0.79 per share.
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.